Evolving chemotherapeutics

New partnership to fund Deflexifol bridging trial and FDA meeting

Fivephusion has concluded a drug development partnership deal with Detsamma Investments Pty Ltd. Detsamma will fund the further development of Deflexifol, including completing a bridging trial to gather extra data sought by the FDA.

Detsamma Investments plans to complete the bridging trial in 2020, and follow this with a pre-IND meeting with the FDA.

Detsamma Investments remains open to out-licensing or development partnership discussions to complete the planned pivotal trial for Deflexifol.